MedPath
HSA Approval

ORREPASTE 0.1% w/w

SIN11484P

ORREPASTE 0.1% w/w

ORREPASTE 0.1% w/w

April 9, 2001

ZUELLIG PHARMA PTE. LTD.

ZUELLIG PHARMA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZUELLIG PHARMA PTE. LTD.
Licence HolderZUELLIG PHARMA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

PASTE

**RECOMMENDED DOSAGE :** Apply a small dab (about ¼ inch) to the lesion at bedtime. Depending on the severity of symptoms, it may be necessary to apply twice to three times daily.

SUBMUCOSAL

Medical Information

**INDICATIONS :** Adjunctive treatment and for temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.

**CONTRAINDICATIONS :** This preparation is contraindicated in patients with a history of hypersensitivity to any of its components and propylene glycol. Because it contains a corticosteroid, the preparation is contraindicated in the presence of fungal, viral or bacterial infections of the mouth or throat.

D07AB09

triamcinolone

Manufacturer Information

ZUELLIG PHARMA PTE. LTD.

HOE PHARMACEUTICALS SDN BHD

Active Ingredients

TRIAMCINOLONE ACETONIDE

0.1% w/w

Triamcinolone

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.